Study met primary endpoint (p-value = 0.012)First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG Results support planned Supplemental Biologics License Application (sBLA) submission to U.S. Food and Drug Administration (FDA) to expand label into oMG Regulated Information – Inside Information  February 26, 2026, 6:30 AM CET    Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives o ...

Core Insights - The analysis focuses on argenx SE's lead product, VYVGART HYTRULO, and a recent safety event related to its use in CIDP patients, indicating that the transition from IVIG to VYVGART HYTRULO may be the primary concern rather than the drug itself [1] Group 1 - The safety event discussed pertains to the transition process for CIDP patients moving from IVIG to VYVGART HYTRULO [1]